Application of sarpogrelate containing pharmaceutical composition in treatment of diabetic nephropathy
A kind of sarpogrelate, drug technology, applied in the field of medicine
Inactive Publication Date: 2018-04-20
CHINA PHARM UNIV
View PDF3 Cites 2 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
[0011] At present, there is no report on the combined use of sarcogrelate and / or serotonin synthesis inhibitors for the treatment of diabetic nephropathy
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0163] 1 part by weight of sagrester, 5 parts by weight of p-chlorophenylalanine, and dextrin and other commonly used adjuvants for granules are prepared into granules by conventional technology.
Embodiment 2
[0165] 1 part by weight of sagrester, 2 parts by weight of p-chlorophenylalanine, and microcrystalline cellulose and other commonly used auxiliary materials for tablets are compressed into tablets.
Embodiment 3
[0167] 2 parts by weight of sagrellate, 1 part by weight of p-chlorophenylalanine, and dextrin and other commonly used adjuvants for granules are used to make granules by conventional technology, and then poured into hard capsule skins to make capsules.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more PUM
Login to view more Abstract
The invention belongs to the technical field of pharmaceuticals, discloses application of a sarpogrelate containing pharmaceutical composition in treatment of diabetic nephropathy, and specifically discloses the application of a compound pharmaceutical composition taking sarpogrelate and 5-hydroxytryptamine synthesizing inhibitor as pharmaceutical active components in preparation of drugs for treating diabetic nephropathy. The test shows that gene silencing 5-HT synthetase and a 5-HT 2 receptor show good effect on inhibiting in-vitro culture and high glucose-induced oxidative stress of human renal mesangial cell strain, proinflammatory factor and chemotactic factor, and meanwhile, the gene silencing 5-HT synthetase system (Tph1 or AADC) and a 5HT 2 receptor are capable of greatly inhibiting high glucose-inducing effect and performing synergistic effect. With the adoption of the pharmaceutical composition, the diabetic nephropathy caused by high-fat feed feeding and streptozotocin induced diabetic nephropathy can be obviously treated; compared with simple prescription, the compound prescription is high in attenuation, and the lethal amount of mice orally taking the drug is obviouslyhalved.
Description
technical field [0001] The invention belongs to the field of medicine, and relates to the use of a pharmaceutical composition containing sagrelor for treating diabetic nephropathy, in particular to a compound drug combination of a serotonin 2 receptor antagonist sagrelate and a 5-serotonin synthesis inhibitor Drugs for the treatment of diabetic nephropathy purposes. Background technique [0002] Diabetic nephropathy (DN) is the most serious complication of diabetes. In recent years, the number of patients worldwide has been increasing, and it has become one of the main causes of end-stage renal disease. The pathogenesis of DN is complex and has not been fully understood so far. At present, it is believed that it is mainly related to metabolic disorders (hyperglycemia, hyperlipidemia, etc.) and hemodynamic disorders. When DN occurs, cells in the kidney produce oxidative stress under the stimulation of high glucose and other factors, secrete a large number of pro-inflammatory...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more Application Information
Patent Timeline
Login to view more Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/225A61P3/10A61P13/12A61K31/198A61K31/165
CPCA61K45/06A61K31/165A61K31/198A61K31/225A61K2300/00
Inventor 傅继华
Owner CHINA PHARM UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap